| abstract |
Use of a hedgehog antagonist for the preparation of a pharmaceutical composition to inhibit undesired cell proliferation, whereby the cells are determined to overexpress a gli-1 gene, AND whereby said antagonist causes decreased cell proliferation, in that said unwanted cell proliferation is benign prostatic hyperplasia or cancer, and wherein said cancer is selected from cancer associated with one or more of the prostate, breast and bladder tissues, where the hedgehog antagonist is an inhibitor of the hedgehog signaling pathway and is selected from: a) an hedgehog antibody that binds to a hedgehog protein, or b) a compound having the structure of compound B: ** Formula ** |